 | • レポートコード：D0-MOR-AP0700 • 出版社/出版日：Mordor Intelligence / 2020年4月20日 • レポート形態：英文、PDF、121ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：健康管理 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、不妊薬の世界市場について調査・分析した資料で、不妊薬の市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。 |
The infertility drugs market studied was anticipated to grow with a CAGR of 6.1% during the forecast period. The major factors attributing to the growth of the market are significant changes in lifestyle which contributed to a rise in the number of (PCOS) Polycystic ovary syndrome cases, urinary and breast cancers. Also, a rise in the prevalence of cancers resulting in increased exposure to radiation which leads to infertility. As per the U.S. Department of Health and Human Services (HHS) report, in 2019, PCOS is a major health problem that affects 1 in 10 women of childbearing age across the globe. Thus, rising gynecological disorders resulting in decreased fertility rate is likely to fuel the global infertility drugs market.
Key Market Trends
Female Infertility Drugs Segment is Expected to Hold the Major Market Share in the Infertility Drugs Market
The Female infertility drugs segment is expected to dominate the industry over the forecast period. The lucrative growth of the segment can be attributed to the higher incidences of infertility, misconception due to women compared to men and a mixture of male and female problems. The major cause of infertility among women is an increased prevalence of thyroid, breast cancers which necessitated higher exposure to radiation leading to steep decrease in fertility rate. For instance, according to the factsheet published by the National Institutes of Health, the fertility rate of women decreases by half in their 30s, as fertile as they are in their early 20s. Also, the report states that women’s chance of conception declines significantly after age 35.6 whereas male fertility declines gradually and among the women with any type of cancer. Also, a rise in cigar smoking, alcohol consumption and rising incidences of various disorders like PCOS and uterine fibroids result in higher demand fueling the growth of the segment.
North America Dominates the Market and Expected to do Same in the Forecast Period.
North America is expected to dominate the global infertility drugs market throughout the forecast period. This dominance is mainly owing to rising incidences of menopausal disorders, urinary infections, thyroid problems, endometriosis, and others due to busy lifestyles and a rise in stress among women. As per the Centers for Disease Control and Prevention CDC report published in 2019, PCOS affects around 6% to 12% representing more than 5 million women of reproductive age. Also, a steep rise in oligozoospermia, varicocele, diabetes, and others among men in the United States propels the revenue share in the region. Additionally, the presence of more number of reproductive endocrinologists along with advanced healthcare infrastructure fuels the market growth in the United States. Government expenditure for the women healthcare awareness with growing geriatric women population and early product launches are likely to further contribute its outstanding share in the global market revenue.
Competitive Landscape
The global infertility drugs market is moderately competitive and consists of several major players. Some prominent players in the market are implementing various strategies such as launching new products and making acquisitions to consolidate their market positions across the globe. Furthermore, a steep rise in the availability of public fundings to develop these drugs is also expected to fuel the market. In December 2019, Allergan announced that its product PrFIBRISTAL was publicly funded through the Ontario Drug Benefit (ODB) Formulary and the Non-Insured Health Benefits (NIHB) Program. PrFIBRISTAL is used in first-in-class medical treatment for uterine fibroids, which lead to infertility. The uterine fibroids are the most common gynecological tumors which affect almost one-in-three Canadian women of reproductive age. Such encouraging public funds, innovative approaches to treat infertility are likely to positively impact the market during the forecast period. Some of the companies which are currently dominating the market are Mallinckrodt Pharmaceuticals, Ferring Pharmaceuticals Inc, Merck KGaA, Pfizer Inc, and Novartis AG
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Global Prevalence of Stress and Life-style Disorders among Men and Women
4.2.2 Rise in Healthcare Awareness along with Increasing Aging Female Population
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework that Delays the Approval of Products
4.3.2 Expensive Patented Products
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Gonadotrophins
5.1.2 Aromatase Inhibitors
5.1.3 Selective Estrogen Receptor Modulators (SERMs)
5.1.4 Follicle Stimulating Hormones
5.1.5 Tricyclic Antidepressants
5.1.6 Biguanides
5.1.7 Others
5.2 By End-user
5.2.1 Male
5.2.2 Female
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Takeda Pharmaceutical Company Limited
6.1.3 Mallinckrodt Pharmaceuticals
6.1.4 Ferring Pharmaceuticals Inc.
6.1.5 Merck KGaA.
6.1.6 Pfizer Inc.
6.1.7 Novartis International AG.
6.1.8 Bayer AG.
6.1.9 Zydus Pharmaceuticals
6.1.10 F. Hoffmann-La Roche Ltd.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS